Elobixibat is a once-daily, orally available potent and selective IBAT inhibitor that has shown evidence of improved secretion and motility in the large bowel without a negative impact on important functions in the small intestine.
Elobixibat works to increase bile acid levels in the colon by inhibiting reabsorption of bile acids from the small intestine to the liver. It has minimal systemic exposure at therapeutic doses, acts locally in the gut and is excreted substantially intact, which may reduce the risk of systemic side effects and undesirable drug-drug interactions compared with drugs that have broad distribution in the body. EA Pharma Co., Ltd., a company formed via a 2016 combination of Eisai’s GI business with Ajinomoto Pharmaceuticals and focused on the gastrointestinal disease space, is the exclusive licensee of elobixibat for the treatment of gastrointestinal disorders in Japan and other select countries in Asia (not including China).
A JNDA for elobixibat to treat chronic constipation was submitted in Japan in February 2017, following highly statistically significant results from a Phase 3 clinical trial of elobixibat in chronic constipation conducted by EA Pharma in Japan. If approved, EA Pharma plans to co-market elobixibat in Japan with Mochida Pharmaceutical Co., Ltd.
Albireo owns commercial rights to elobixibat in the United States, Europe and otherwise outside of the territories licensed to EA Pharma.